Nuvectis Pharma, Inc. financial data

Symbol
NVCT on Nasdaq
Location
1 Bridge Plaza, Suite 275, Fort Lee, NJ
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 331 % -26.4%
Debt-to-equity 43.3 % +51.5%
Return On Equity -152 % -14.6%
Return On Assets -106 % -2.78%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.7M shares +8.25%
Common Stock, Shares, Outstanding 18.7M shares +8.87%
Entity Public Float 60M USD -6.25%
Weighted Average Number of Shares Outstanding, Basic 16.9M shares +11.3%
Weighted Average Number of Shares Outstanding, Diluted 16.9M shares +11.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.4M USD -7.67%
General and Administrative Expense 7.71M USD +9.46%
Operating Income (Loss) -22.1M USD +2.33%
Net Income (Loss) Attributable to Parent -21.1M USD +5.5%
Earnings Per Share, Basic -1.29 USD/shares +17.3%
Earnings Per Share, Diluted -1.29 USD/shares +17.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18.1M USD -26.4%
Other Assets, Current 182K USD -46.6%
Assets, Current 18.3M USD -26.6%
Assets 18.3M USD -26.6%
Accounts Payable, Current 1.85M USD +2.39%
Employee-related Liabilities, Current 3.61M USD +96.8%
Accrued Liabilities, Current 310K USD -45.7%
Liabilities, Current 5.77M USD +25.2%
Liabilities 5.77M USD +25.2%
Retained Earnings (Accumulated Deficit) -62.8M USD -50.6%
Stockholders' Equity Attributable to Parent 12.5M USD -38.4%
Liabilities and Equity 18.3M USD -26.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.36M USD +8.77%
Net Cash Provided by (Used in) Financing Activities 4.7M USD +1763%
Common Stock, Shares Authorized 60M shares 0%
Common Stock, Shares, Issued 18.7M shares +8.87%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.1M USD -26.4%
Deferred Tax Assets, Valuation Allowance 14.5M USD +69%
Deferred Tax Assets, Gross 14.5M USD +69%
Deferred Tax Assets, Operating Loss Carryforwards 9.63M USD +57.3%
Additional Paid in Capital 75.4M USD +21.4%
Deferred Tax Assets, Net of Valuation Allowance 0 USD